2 January 2024 in BMC Public Health
RFRamadan Abdelmoez Farahat
Ramadan Abdelmoez Farahat
+3
Introduction: Mpox is a zoonotic viral disease that emerged in May 2022 and has since shown a high prevalence in non-mpox-endemic areas, resulting in an outbreak that caused more than 84,000 cases in 110 countries around the globe. Several vaccines are available to prevent the disease, and multiple studies have been conducted to assess the attitudes of different populations toward receiving the mpox vaccine. This study systematically reviews all the studies conducted on mpox vaccine acceptance/hesitancy among healthcare workers. Methods: A systematic literature search was conducted through four electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, up to March 2023. Studies that described mpox vaccine acceptance/hesitancy among healthcare workers were included, and the data were extracted using a uniform extraction sheet. Following the extraction, the meta-analysis included ten studies with 7322 healthcare workers. Three researchers independently assessed the risk of bias in the included study using the Newcastle–Ottawa Scale (NOS). Results: Ten studies were included in the review. This review indicates that the prevalence of mpox vaccine acceptance was 58.5%, and the prevalence of mpox vaccine hesitancy was 41.5%. There was a higher prevalence of acceptance in countries located in Asian and African areas compared to those in North America and Europe, estimated at 68% and 44.3%, respectively. Among the studies conducted solely among physicians, there was a high prevalence of mpox vaccine acceptance, at 77.1%, compared to 49% in studies that included all healthcare workers. Conclusion: There is a significant variation in the prevalence of mpox vaccine acceptance among different populations. Further research is needed to identify the factors that contribute to this variation and to develop interventions to increase vaccine acceptance. In addition, it is important to promote research on mpox vaccine acceptance and hesitancy among healthcare workers in countries where data is limited. This research will help policymakers develop effective policies to increase acceptance and reduce the disease burden.
23 April 2024 in Journal of Gastrointestinal Surgery
6 October 2021 in Human Vaccines & Immunotherapeutics
Background: Vaccination has been known to reduce morbidity and mortality of infectious diseases since the emergence of the 1st vaccine in the 18th century. That’s why global efforts are directed toward finding a vaccine for COVID-19 in order to eliminate its threat. The current pandemic of COVID-19 has changed the world affecting all fields significantly as a result of the preventive measures including locking down, social distancing, obligatory mask wearing, stopping flights, etc. The medical field is clearly the most significantly affected starting from altering most of the research efforts toward the new virus passing through the inadequate number of physicians as well as unavailable intensive care unit (ICU) beds. In order to break the restricted preventive measures, we need to minimize the newly infected cases which can be achieved by reaching adequate herd immunity. Moreover, calculating the basic reproduction number (R0) of COVID-19 is crucial to estimate the herd immunity threshold (Ic). Methods: In this review, we searched PubMed for studies that mentioned the R0 of COVID_19, SARS, and MERS as well as measles, Zika and dengue virus to calculate the herd immunity threshold and the minimal vaccination coverage. Results: The value of R0 could vary for the same disease and consequently the herd immunity threshold as well as the vaccination coverage. The R0 of COVID-19 ranged widely through various articles from 1.4 to 6.68. As a result, the herd immunity threshold would range from 28.57% to 85.03%. However, the vaccination coverage depends also on the effectiveness of the vaccine which is still unknown. Conclusion: The calculations of vaccination coverage include many variables such as the R0 of the disease, Ic that depends on that value as well as sensitivity and specificity of the vaccine itself.
10 November 2022 in European Archives of Oto-Rhino-Laryngology
Background: Several reports examined the survival of laryngeal cancer (LC) patients, most of these studies only focused on the prognosis of the disease, and just a small number of studies examined non-cancer-related causes of death. The objective of the current study is to investigate and quantify the most common causes of deaths following LC diagnosis. Methods: The data of 44,028 patient with LC in the United States diagnosed between 2000 and 2018 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program and analyzed. We stratified LC patients according to various demographic and clinical parameters and calculated standardized mortality ratios (SMRs) for all causes of death. Results: Over the follow-up period, 25,407 (57.7%) deaths were reported. The highest fatalities (11,121; 43.8%) occurred within 1–5 years following LC diagnosis. Non-cancer causes of death is the leading cause of death (8945; 35.2%), followed by deaths due to laryngeal cancer (8,705; 34.3%), then other cancers deaths (7757; 30.5%). The most common non-cancer causes of death were heart diseases (N = 2953; SMR 4.42), followed by other non-cancer causes of death (N = 1512; SMR 3.93), chronic obstructive pulmonary diseases (N = 1420; SMR 4.90), then cerebrovascular diseases (N = 547; SMR 4.28). Compared to the general population, LC patients had a statistically significant higher risk of death from all reported causes. Conclusions: Non-cancer causes of death is the leading cause of death in LC patients, exceeding deaths attributed to LC itself. These findings provide important insight into how LC survivors should be counselled regarding future health risks.
8 August 2022 in Travel Medicine and Infectious Disease